Michael Hater, MD
Ophthalmology · Cincinnati, OHNPI 1982643904
Payments from drug & device makers
Across 229 payments — averaging $21.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sun Pharmaceutical Industries Inc.$1K
- Bausch & Lomb Americas Inc.$724
- Oyster Point Pharma, Inc.$525
- Novartis$437
- Dompe US, Inc.$278
- Alcon$259
- plus $2K from 17 others
What the payments were for
- Food & beverage$4,986100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sun Pharmaceutical Industries Inc. | 60 | $1,043 |
| Bausch & Lomb Americas Inc. | 25 | $724 |
| Oyster Point Pharma, Inc. | 22 | $525 |
| Novartis | 23 | $437 |
| Dompe US, Inc. | 14 | $278 |
| Alcon | 12 | $259 |
| Kala Pharmaceuticals, Inc. | 14 | $248 |
| Amgen(2 entities) | 8 | $238 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 11 | $205 |
| AbbVie | 11 | $165 |
| Glaukos Corporation | 3 | $113 |
| Tarsus Pharmaceuticals, Inc. | 4 | $113 |
| Genentech USA, Inc. | 1 | $105 |
| Lombart Brothers, Inc. | 3 | $86 |
| Harrow Eye, LLC | 3 | $84 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $65 |
| Mallinckrodt Enterprises LLC | 3 | $64 |
| Biotissue Holdings Inc. | 3 | $56 |
| Aerie Pharmaceuticals, Inc. | 2 | $53 |
| Eyepoint US, Inc. | 1 | $44 |
| Eyevance Pharmaceuticals LLC | 3 | $43 |
| Ivantis, Inc | 1 | $22 |
| Dutch Ophthalmic, USA | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,986 in reported general payments places this provider in the 80th percentile of 640 ophthalmology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 62 | $75,034 |
| XiidraLifitegrast | 14 | $22,663 |
| Prednisolone Acetate | 545 | $22,020 |
| ProlensaBromfenac Sodium | 60 | $20,857 |
| MieboPerfluorohexyloctane/Pf | 27 | $20,218 |
| Lotemax SmLoteprednol Etabonate | 70 | $17,295 |
| Loteprednol Etabonate | 101 | $15,267 |
| LumiganBimatoprost | 28 | $13,841 |
| VevyeCyclosporine | 12 | $12,601 |
| BesivanceBesifloxacin Hcl | 58 | $12,459 |
| Fluorometholone | 158 | $11,128 |
| Cyclosporine | 11 | $7,020 |
| MoxifloxacinMoxifloxacin Hcl | 245 | $5,635 |
| Bromfenac Sodium | 26 | $5,464 |
| CombiganBrimonidine Tartrate/Timolol | 11 | $3,928 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $165 | $92,802101 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Lotemax Sm, Loteprednol Etabonate, Besivance | $205 | $65,879289 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo | $724 | $42,88141 claims |
| Harrow Eye, LLCVevye | $84 | $12,60112 claims |
| Sun Pharmaceutical Industries Inc.Bromsite | $1,043 | $3,63415 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 640 ophthalmology providers in Ohio.
Other ophthalmology in Cincinnati
- Daniel MillerCincinnati$2.3M
- Michael SnyderCincinnati$1.3M
- Christopher RiemannCincinnati$985K
- Robert SiskCincinnati$831K
- Anup KhatanaCincinnati$794K
- Robert OsherCincinnati$720K
- Haroon ChaudhryCincinnati$708K
- Christopher DevineCincinnati$623K
- Robert BenzaCincinnati$224K
- Linda GreffCincinnati$168K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.